CHARACTERISTICS OF SIROLIMUS-ASSOCIATED INTERSTITIAL PNEUMONITIS IN RENAL TRANSPLANT PATIENTS

@article{Morelon2001CHARACTERISTICSOS,
  title={CHARACTERISTICS OF SIROLIMUS-ASSOCIATED INTERSTITIAL PNEUMONITIS IN RENAL TRANSPLANT PATIENTS},
  author={E. Morelon and Marc Stern and Dominique Israel-Biet and Jean-Michel Correas and Claire Danel and Marie-France Mamzer-Bruneel and Marie No{\"e}lle Peraldi and Henri Kreis},
  journal={Transplantation},
  year={2001},
  volume={72},
  pages={787-790}
}
Background. Sirolimus, a promising new immunosuppressive drug for organ transplantation, is currently associated with side effects, such as thrombocytopenia and hyperlipidemia. Methods. Eight renal transplant recipients, who developed unexplained interstitial pneumonitis during sirolimus therapy, were extensively re-screened for all causes of pneumonitis. Results. Interstitial pneumonitis was constantly characterized by bilateral interstitial infiltrates on chest x-rays and lung computed… 

Interstitial pneumonitis associated with sirolimus

TLDR
The patient was a 53 year-old male with a first renal transplant under immunosuppression with tacrolimus and sirolimus, who presented progressive dyspnoea, non-productive cough, chest pain and low-grade fever for 3 weeks, and drug-induced toxicity was suspected.

Patterns of Pulmonary Complications Associated with Sirolimus

TLDR
The patterns of pulmonary adverse effects associated with sirolimus in 4 renal transplant recipients who developed pulmonary opacities on chest radiograph were studied, which were proved to be noninfectious in origin.

Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients.

  • J. DelgadoJ. Torres C. S. de la Calzada
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2006

Sirolimus-induced interstitial pneumonitis in a renal transplant recipient

TLDR
Sirolimus was discontinued and the patient improved gradually, with complete disappearance of the symptoms and normalization of CRP level within 2 weeks, and high-resolution thoracic CT scan returned to normal 4 months later.

Sirolimus induced granulomatous interstitial pneumonitis

A Pediatric Case of Sirolimus-Associated Pneumonitis After Kidney Transplantation.

TLDR
A case of a 17-year-old male kidney transplant recipient who developed rapid-onset respiratory failure, necessitating mechanical ventilation and acute renal replacement therapy for ultrafiltration secondary to sirolimus-induced pneumonitis is reported.

SIROLIMUS-ASSOCIATED PULMONARY TOXICITY

TLDR
The temporal relationship between sirolimus exposure and onset of pulmonary symptoms in the absence of infectious causes and other alternative pulmonary disease and the associated clinical and radiologic improvement after its cessation suggests a causal relationship.

SIROLIMUS ASSOCIATED INTERSTITIAL PNEUMONITIS IN A RENAL TRANSPLANT PATIENT: IS IT A HYPERSENSITIVITY RESPONSE?

TLDR
It is thought that bronchoalveolar lavage cell counts may provide some information about the mechanism of sirolimus-induced pneumonitis and observations in animals and humans indicate that this agent may cause lung injury in selected cases via differential regulation of the Th1/Th2 lymphocyte balance.
...

References

SHOWING 1-10 OF 10 REFERENCES

Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.

TLDR
It is important that all patients receiving methotrexate be educated concerning this potential adverse reaction and instructed to contact their physicians should significant new pulmonary symptoms develop while undergoing therapy, and if metotrexate pneumonitis is suspected, methotRexate should be discontinued.

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

TLDR
Patients and graft survival and the incidence of biopsy-proven acute rejection at 12 months were comparable between sirolimus and CsA, whereas safety profiles were different, suggesting that siro Limus may be used as primary therapy for the prevention of acute rejection.

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

TLDR
Results at 12 months suggest that sirolimus can be used as base therapy in the prophylaxis of acute renal transplant rejection, and has a safety profile that differs from CsA.

Drugs that may injure the respiratory system.

TLDR
The preparation of a table listing most drugs capable of injuring the respiratory system was appropriate and designed to provide the information currently available on such drugs in a readily accessible form.

Immunopharmacology of rapamycin.

TLDR
Accumulating data suggest that mTOR functions in a previously unrecognized signal transduction pathway required for the progression of IL-2-stimulated T cells from G1 into the S phase of the cell cycle.

BRONCHIOLITIS OBLITERANS AND ORGANIZING PNEUMONIA IN RENAL TRANSPLANT RECIPIENTS

Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients.

Immunosuppressive strategies in transplantation

Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A.